首页 | 本学科首页   官方微博 | 高级检索  
检索        

度洛西汀联合硫辛酸治疗糖尿病周围神经病变性疼痛的疗效观察
引用本文:沈柿芬,郭道骝.度洛西汀联合硫辛酸治疗糖尿病周围神经病变性疼痛的疗效观察[J].临床药物治疗杂志,2016(2):65-68.
作者姓名:沈柿芬  郭道骝
作者单位:1. 浙江省余姚市第三人民医院内科,浙江 余姚,315400;2. 南京医科大学附属无锡人民医院神经内科,南京,214023
摘    要:目的:探讨度洛西汀联合硫辛酸治疗糖尿病周围神经病变性疼痛的有效性及安全性。方法:将78例糖尿病周围神经病变性疼痛患者随机分为两组,西汀组口服度洛西汀,联合组口服度洛西汀和静脉滴注硫辛酸,比较两组疗效。结果:两组治疗后正中神经感觉传导速度(median nerve conduction velocity,MNCV)、腓总神经感觉传导速度(phil nerve conduction velocity,PNCV)、尺神经感觉传导速度(ulnar nerve conduction velocity,UNCV)均显著提高(P<0.05);联合组治疗4周、8周后MNCV、PNCV、UNCV均显著高于治疗前及同期西汀组(P<0.05);两组治疗后疼痛强度简易评述量表(VRS)、数字疼痛强度量表(NRS)评分显著下降(P<0.05);联合组治疗4周、8周后VRS、NRS评分显著低于治疗前及同期西汀组(P<0.05);两组不良反应发生率(30.77%和23.08%)差异无统计学意义(P>0.05);两组治疗前、治疗8周后胆固醇(TC)、甘油三酯(TG)、丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、血肌酐(SCr)指标水平均无显著性变化(P>0.05)。结论:度洛西汀联合硫辛酸治疗糖尿病周围神经病变性疼痛,能有效改善患者神经功能,减轻疼痛症状,且安全可靠。

关 键 词:度洛西汀  硫辛酸  糖尿病周围神经病变性疼痛  安全性

Therapeutic effect analysis of duloxetine hydrochloride combined with alpha-lipoic acid in treatment of diabetic peripheral neuropathic pain
Abstract:Objective:By comparing duloxetine combination with alpha-lipoic acid and duloxetine in the therapeutic effect of painful diabetic neuropathy, to explore the efficacy and safety of duloxetine combination with alpha-lipoic acid treatment on diabetic peripheral neuropathic pain (DPNP) is optimal.Methods:78 cases with painful diabetic neuropathy of type 2 diabetes were recruited from our department and randomly divided into two groups, which were duloxetine in combination with alpha-lipoic acid group and duloxetine treatment group.Results: Compared to baseline, median nerve sensory conduction velocity (MNCV), Phil nerve conduction velocity (PNCV) and ulnar nerve conduction velocity (UNCV) of both groups were better (P<0.05) after treatments; MNCV, SNCV and UNCV of combined treatment group were signiifcantly higher (P<0.05) than own baseline and duloxetine single-agent group after four and eight weeks; After treatment, VRS and NRS scores of both groups were signiifcantly lower (P<0.05); VRS and NRS scores of combined treatment group after four weeks or eight weeks were signiifcantly lower than its baseline and duloxetine single-agent group with a signiifcant difference (P<0.05). There was no signiifcant difference in the incidence of adverse events between two groups (30.77% vs 23.08%,P>0.05). Before treatment, no statistically signiifcant differences were detected in total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum creatinine (SCr) between two groups (P>0.05).Conclusion:Duloxetine hydrochloride combined with alpha-lipoic acid has a good analgesic and neuroprotection effect on DPNP. Moreover, this treatment strategy is also safe and effective.
Keywords:duloxetine  alpha-lipoic acid  diabetic peripheral neuropathic pain  safety
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号